EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC 4.0

Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial

Ryota Usui iD, Yoshiyuki Hamamoto iD, Masahiro Imura, Yasuhiro Omori, Yuji Yamazaki, Hitoshi Kuwata, Hisato Tatsuoka iD, Kazuhiro Shimomura, Kenta Murotani iD, Yuichiro Yamada iD, Yutaka Seino iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16086 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Ryota Usui und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Incretins, Hypoglycemic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sumitomo Pharma Co..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Imeglimin is a new oral anti‐diabetic drug with a similar structure to that of metformin; however, unlike metformin, clinical trials indicate that imeglimin elicits its glucose‐lowering effect mainly by enhancement of insulin secretion. The comparative effects of the two drugs on incretin secretion remains to be elucidated. Materials and Methods A single‐center, open‐label, randomized controlled trial was conducted in patients with type 2 diabetes who were drug‐naïve or were on a single oral hypoglycaemic agent (OHA). For patients taking a single OHA, an 8‐week washout period was employed before randomization. Participants were randomized to the imeglimin group (IME, 2000 mg/day) or the metformin group (MET, 1000 mg/day), and OGTT was performed before treatment and after 12 and 24 weeks of treatment.

Results

The reduction in HbA1c at 24 weeks was similar in IME and MET. OGTT revealed a comparable decrease in post‐challenge blood glucose excursion in both groups, but insulin levels were increased only in IME. Total and active glucagon‐like peptide‐1 (GLP‐1) levels were increased in both IME and MET; however, total and active glucose‐dependent insulinotropic peptide (GIP) levels were increased only in IME. Interestingly, while an increase in insulin levels in IME was positively correlated with an increase in GLP‐1 at 12 weeks, it was correlated only with an increase in GIP at 24 weeks.

Conclusions

Unlike metformin, imeglimin enhances GIP secretion as well as GLP‐1 secretion, in addition to its direct insulinotropic mechanism of glucose control, emphasizing its potential as a therapeutic option in the treatment of patients with diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2IncretinsHypoglycemic AgentsInsulinBlood GlucoseGlycated HemoglobinHumansMaleFemaleMiddle AgedInsulin SecretionGlucagon-Like Peptide 1Glucose Tolerance TestAgedTriazines

Stichwörter der Autor:innen

imegliminincretinmetforminrandomized controlled trial

Substanzen

MetforminIncretinsHypoglycemic AgentsInsulinimegliminBlood GlucoseGlycated HemoglobinGlucagon-Like Peptide 1hemoglobin A1c protein, humanTriazines

Autor:innen und Institutionen

  • Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
  • Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan.
  • Research and Development department, General Incorporated Association Kansai Healthcare Science Informatics, Kyoto, Japan.
  • Department of Pharmacy, Aichi Cancer Center Hospital, Aichi, Japan.
  • Biostatistics Center, Kurume University, Fukuoka, Japan.

ORCID-Profile: Ryota Usui, Yoshiyuki Hamamoto, Hisato Tatsuoka, Kenta Murotani, Yuichiro Yamada, Yutaka Seino

Förderung

  • Sumitomo Pharma Co.

Zitieren

APA

Usui, R., Hamamoto, Y., Imura, M., Omori, Y., Yamazaki, Y., Kuwata, H., Tatsuoka, H., Shimomura, K., Murotani, K., Yamada, Y., & Seino, Y. (2025). Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16086

Vancouver

Usui R, Hamamoto Y, Imura M, Omori Y, Yamazaki Y, Kuwata H, et al. Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16086

BibTeX
@article{Usui2025,
  author = {Usui, Ryota and Hamamoto, Yoshiyuki and Imura, Masahiro and Omori, Yasuhiro and Yamazaki, Yuji and Kuwata, Hitoshi and Tatsuoka, Hisato and Shimomura, Kazuhiro and Murotani, Kenta and Yamada, Yuichiro and Seino, Yutaka},
  title = {Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16086}
}
Kostenlos starten →